Poster 28
- Jun 7, 2023
- 1 min read
Efficacy and Safety of Monotherapy Amlitelimab, a Non-Depleting Anti-OX40 Ligand Antibody, in Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the Pivotal COAST-1 and COAST-2 Phase 3 Trials
Linda Stein Gold, H. Chih-ho Hong, Pedro Mendes-Bastos, Nina Magnolo, Jinhua Xu, Ken Igawa, Guy Gherardi, Pei Li, Karl Yen, Charlotte Bernigaud, Benjamin Planquette


